Research Article
Volume 8 Issue 9 - 2020
Metformin Used for Weight Loss by Non-Diabetic Sudanese Females
Abdelaziz SI1 and Miyada AM2
1Assistant Professor of Medicine, Consultant Internal Medicine and Endocrine, Soba University Hospital, University of Khartoum, Khartoum, Sudan
2Clinical Pharmacist, Mcs, Omdurman Islamic University, Omdurman, Sudan
*Corresponding Author: Abdelaziz SI, Assistant Professor of Medicine, Consultant Internal Medicine and Endocrine, Soba University Hospital, University of Khartoum, Khartoum, Sudan.
Received: April 04, 2020; Published: August 11, 2020


Metformin, a principle Biguanide, is the main anti-diabetic agent for the treatment of T2DM. It reduces the insulin resistance associated with T2 DM. In addition, obesity, which is found to have a similar pathogenesis may be affected by treatment with Metformin. Young obese non-diabetic females have taken an interest in taking Metformin over-the-counter to lose weight.

Here we studied the practice of using Metformin for weight loss. We performed a cross-sectional study on 50 women, selected randomly at Khartoum State between November to December 2017. All of whom were females and 37.3% more than 30 years old. The majority had a BMI of 35 kg/m2.

Fifty-eight percent were not married, (28%) and (4%) were pharmacists and physicians respectively and 39.2% used only 500 mg of Metformin once a day. Ninety percent had abdominal disturbance, 58.8% stopped Metformin use because of side effects, 64.7% obtained metformin from the pharmacy as over the counter (OTC) medicines. Thirty percent obtained the information about metformin use from the social media or their friends, 58.8% observed weight loss by more than 5 kg. Fifty-four point nine percent and fifty-eight point eight percent had been on diet and exercise programs respectively, 64.7% were satisfied with their result. There were significant associations between weight reduction with, dose used, diet and exercise.

We conclude that women who used Metformin over the counter had a good experience with it especially when combined with diet and exercise.

Keywords: Metformin; Obesity; Weight Loss; Insulin Resistance


  1. “Metformin Hydrochloride". The American Society of Health-System Pharmacists (2016). 
  2. Crowley Matthew J., et al. “Clinical Outcomes of Metformin Use in Populations with Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review". Annals of Internal Medicine 166.3 (2017): 191. 
  3. Bennett WL., et al. “Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations". Annals of Internal Medicine 154.9 (2011): 602-613. 
  4. Inzucchi SE., et al. “Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetes Care 35.6 (2012): 1364-1379. 
  5. Golay A. “Metformin and body weight”. International Journal of Obesity 32.1 (2008): 61‐72.
  6. Lachin JM., et al. “Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program”. Diabetes 56.4 (2007): 1153‐1159.
  7. Velazquez EM., et al. “Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy". Metabolism: Clinical and Experimental 43.5 (1994): 647-654. 
  8. Al-Inany H and Johnson N. "Drugs for anovulatory infertility in polycystic ovary syndrome". British Medical Journal 332.7556 (2006): 1461-1462. 
  9. Sivalingam VN., et al. “Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications". Human Reproduction Update 20.6 (2014): 853-868. 
  10. Cheung NW. "The management of gestational diabetes" (pdf)”. Vascular Health and Risk Management 5.1 (2009): 153-164. 
  11. Salpeter S., et al. “Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis". Archives of Internal Medicine 163.21 (2003): 2594-602. 
  12. Eurich DT., et al. “Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review". British Medical Journal 335.7618 (2007): 497. 
  13. Fujita Yoshihito and Inagaki Nobuya. "Metformin: New Preparations and Nonglycemic Benefits". Current Diabetes Reports 17.1 (2017): 5. 
  14. Jager J., et al. “Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial". British Medical Journal 340 (2010): c2181. 
  15. Khurana R and Malik IS. "Metformin: safety in cardiac patients". Heart 96.2 (2010): 99-102. 
  16. Buse JB., et al. “The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies”. Diabetes Care 39 (2016): 198-205.
  17. Foretz M., et al. “Metformin: from mechanisms of action to therapies”. Cell Metabolism 20 (2014): 953.
  18. Alexey V Zilov., et al. “Mechanisms of action of metformin with special reference to cardiovascular protection”. Diabetes/Metabolism Research and Reviews (2019): e3173. 
  19. Malin SK and Kashyap SR. “Effects of metformin on weight loss: potential mechanisms”. Current Opinion in Endocrinology, Diabetes and Obesity 21.5 (2014): 323-329. 
  20. Seifarth C., et al. “Effectiveness of metformin on weight loss in non-diabetic individuals with obesity”. Experimental and Clinical Endocrinology and Diabetes 121.1 (2013): 27-31. 
  21. Kara M Levri., et al. “Metformin as Treatment for Overweight and Obese Adults: A Systematic Review”. Annals of Family Medicine 3.5 (2005): 457-461.
  22. Jarskog LF., et al. “Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder”. The American Journal of Psychiatry 170.9 (2013): 1032-1040. 
Citation: Abdelaziz SI and Miyada AM. “Metformin Used for Weight Loss by Non-Diabetic Sudanese Females”. EC Pharmacology and Toxicology 8.9 (2020): 44-54.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to